title: Transfection of truncated bone morphogenetic protein receptor-II into oral squamous cell carcinoma cell line Tca8113 and inhibitory effect on proliferation and inductive effect on apoptosis.
abstract: Bone morphogenetic proteins (BMPs), one of the crucial regulators in embryonic development and bone formation, have been implicated in epithelium-derived tumors. Previous results showed the involvement of overexpression of BMP 2, 4, 5 in the carcinogenesis of oral epithelia. The ability of BMP receptor-II mutant to modify the malignant phenotype of oral squamous cell carcinoma cell line Tca8113 by blocking the BMP signal transduction pathway has been proposed. In this study, a negative truncated mutant of the BMP receptor-II (tBMPR-II) was transfected into Tca8113 cells. The effects were evaluated though RT-PCR, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, BrdU staining, cell cyclin assay, TdT-mediated dUTP nick end labeling (TUNEL) staining, and cell cycle protein detection. Overexpression of tBMPR-II gene transfection truncates the expression of BMPR-II mRNA expression, but not BMP 2, 4, 5. tBMPR-II resulted in a remarkable inhibition of cell proliferation and viability compared with control Tca8113. The inhibitory effects were partly attributed to the induction of apoptosis and cell cycle arrest in G(0) /G(1) accompanied by downregulation of the intracellular cell cycle proteins of cyclin D1 and cyclin-dependent kinases 4, as well as the upregulation of p27 and p57. Loss of BMP signals correlates tightly with suppression of cell proliferation, induction of apoptosis, and benign transformation of Tca8113 cells phenotype.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Fuzhou General Hospital of Nanjing Command, PLA, Fuzhou, China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Fu
authors.forename: Hong-Bing
authors.initials: HB
authors.lastname: Lv
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.forename: Li-Sheng
authors.initials: LS
authors.lastname: He
authors.forename: Yan
authors.initials: Y
authors.lastname: Jin
mesh_terms: D000704:Analysis of Variance; D017209:Apoptosis / Q000235:genetics; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000096:biosynthesis / Q000235:genetics*; D019485:Bone Morphogenetic Proteins / Q000096:biosynthesis / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019938:Cyclin D1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D050761:Cyclin-Dependent Kinase Inhibitor p57 / Q000096:biosynthesis; D015536:Down-Regulation; D006801:Humans; D020287:In Situ Nick-End Labeling; D009062:Mouth Neoplasms / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D018809:Proliferating Cell Nuclear Antigen / Q000096:biosynthesis; D016192:Resting Phase, Cell Cycle; D015398:Signal Transduction / Q000235:genetics; D014162:Transfection
chemical_list: D019485:Bone Morphogenetic Proteins; C493964:CDKN1C protein, human; D050761:Cyclin-Dependent Kinase Inhibitor p57; D018809:Proliferating Cell Nuclear Antigen; C413374:p27 antigen; D019938:Cyclin D1; D051358:Cyclin-Dependent Kinase 4; D052006:Bone Morphogenetic Protein Receptors, Type II